Business Context and Reporting Period
InterCure Ltd. filed a Form 6-K on June 22, 2026, reporting a material corporate event. The filing announces the entry into a binding term sheet for a private placement financing round.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, or existing debt levels. The primary financial data disclosed relates to the proposed capital raise:
- Investment Commitment: Approximately NIS 22 million (US$7 million).
- Securities Issued: Approximately 7.9 million units.
- Unit Composition: One ordinary share and one warrant per unit.
- Warrant Terms: Five-year exercise period at a price of NIS 4.125 per share.
Material Changes
The filing details a significant change in the company's capital structure through the proposed private placement. This transaction is conducted without an underwriter, placement agent, broker, or dealer. The completion of the financing is contingent upon the execution of definitive agreements, receipt of required approvals, and satisfaction of customary closing conditions.
Guidance, Outlook, and Risks
Management commentary is limited to the announcement of the financing led by pharma-focused hedge funds. A specific risk and contingency noted is the requirement for shareholder approval solely regarding the participation of Mr. Alexander Rabinovich, the Company's CEO and a director who beneficially owns approximately 26% of the outstanding ordinary shares. Participation by other investors does not require shareholder approval. The securities are unregistered under the Securities Act of 1933 and cannot be sold in the United States absent registration or an applicable exemption.
Investor Verification Checklist
- Verify the execution of definitive agreements and satisfaction of closing conditions to confirm the transaction will close.
- Confirm the outcome of the shareholder vote regarding CEO Alexander Rabinovich's participation.
- Review the final terms of the warrants and ordinary shares in the definitive agreement.
- Assess the dilution impact of issuing approximately 7.9 million new units on existing shareholders.